` NPCE (Neuropace Inc) vs S&P 500 Comparison - Alpha Spread

NPCE
vs
S&P 500

Over the past 12 months, NPCE has underperformed S&P 500, delivering a return of -16% compared to the S&P 500's 8% growth.

Stocks Performance
NPCE vs S&P 500

Loading
NPCE
S&P 500
Add Stock

Performance Gap
NPCE vs S&P 500

Loading
NPCE
S&P 500
Difference

Performance By Year
NPCE vs S&P 500

Loading
NPCE
S&P 500
Add Stock

Competitors Performance
Neuropace Inc vs Peers

Neuropace Inc
Glance View

Market Cap
339.1m USD
Industry
Health Care

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company’s RNS System is a platform that delivers care for patients suffering from drug-resistant epilepsy and offers a personalized solution and outcomes to the patients suffering from other brain disorders. RNS System is a device that records brain activity data and clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders including depression, impulse control disorders, memory disorders, and post-traumatic stress.

NPCE Intrinsic Value
10.01 USD
Overvaluation 11%
Intrinsic Value
Price
Back to Top